{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-086486","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.096248+00:00","generated_at":"2026-06-08T04:21:41.700770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Emmaus Life Sciences Q3 2023 net income $0.1M vs loss of $0.4M year ago","bullets":["Q3 net revenues $5.0M, up from $4.9M in Q3 2022; nine-month revenues $22.5M vs $12.5M.","Q3 income from operations $0.02M, compared to operating loss of $0.7M in Q3 2022.","Net loss for nine months 2023 was $4.9M ($0.09/share), improved from $10.8M ($0.22/share) in 2022.","Inventory shortage of Endari caused lower Q3 sales; remedied, expects recovery in Q4.","Cash and cash equivalents $1.5M at Sep 30, 2023, down from $2.0M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-086486","json":"https://secwatch.observer/filing/0001213900-23-086486.json","markdown":"https://secwatch.observer/filing/0001213900-23-086486.md","text":"https://secwatch.observer/filing/0001213900-23-086486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/ea188263-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:21:41.700770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06760c46198782eacf48ad42479907c8171175b6","claim":"Emmaus Life Sciences, Inc. reported the three months ended September 30, 2023 results: net income net income of $0.1 million, EPS $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha.","evidence_excerpt":"For the quarter, the company realized net income of $0.1 million, or $0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per share based on approximately 138.4 million weighted average diluted common shares.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Net income","value":"net income of $0.1 million"},{"label":"EPS","value":"$0.00 per share based on approximately 53.6 million weighted average basic common shares and a net loss of $0.01 per sha"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c6a44f70df59d6be955930fbe71770becf6a0c19","claim":"Emmaus Life Sciences, Inc. reported the three and nine months ended September 30, 2023 results: revenue $5.0 million and $22.5 million, respectively.","evidence_excerpt":"Net revenues for the three months and nine months ended September 30, 2023 were $5.0 million and $22.5 million, respectively, compared to $4.9 million and $12.5 million, respectively, for same periods in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$5.0 million and $22.5 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f32b953674469c25a086192d53c2183e5164de15","claim":"Emmaus Life Sciences, Inc. reported the nine months ended September 30, 2023 results: net income net loss of $4.9 million, EPS $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.","evidence_excerpt":"For the nine months ended September 30, 2023, the company reported a net loss of $4.9 million, or $0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2023"},{"label":"Net income","value":"net loss of $4.9 million"},{"label":"EPS","value":"$0.09 per share, based on approximately 52.4 million weighted average basic and diluted common shares"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}